OCUL

NASDAQ · Pharmaceuticals

Ocular Therapeutix Inc

Mid-Cap Stocks Stocks Under $10 Pharmaceutical Stocks Healthcare Stocks

$9.99

-0.15 (-1.48%)

As of Sep 20, 10:07 PM ET ·

OCUL News1 articles

Oculis Shares Plunge as Eye Drop Fails Key Trial Goal

Oculis shares tumbled 23.4% after two Phase 3 trials of OCS-01 eye drops for diabetic macular edema failed to meet the main vision goal. The company will not pursue U.S. approval for this indication.